Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update
August 06, 2024 16:05 ET
|
Rani Therapeutics, LLC
- Announced partnership with ProGen on development of RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity - - Phase 1 study for RT-114 expected to initiate in 2025 - - Completed...
Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment
June 24, 2024 07:00 ET
|
Rani Therapeutics, LLC
~ New RT-114 obesity program combines ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism...